Drug Profile
Research programme: RNA-targeted therapeutics - Bristol-Myers Squibb/Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Santaris Pharma
- Developer Roche
- Class Antisense RNA; Oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Denmark (Parenteral)
- 16 Apr 2013 Early research in Undefined indication in Denmark (Parenteral)